AZD-1390, Yumurtalık Kanseri Hücre Hatlarında Hücre Hareketliliğini Bozar ve ROS Tetiklemeli Apoptotik Hücre Ölümüne Neden Olur

Abstract

Ataksi Telanjiektazi mutasyonu (ATM), serin/treonin kinaz için bir protein kodlayan bir gendir. ATM'nin fosforilasyonu, genomik bütünlüğü koruyarak tümör oluşumunu önler. ATM genindeki somatik mutasyonlar bazı yumurtalık kanseri tiplerinde tespit edilmiştir. Bu nedenle, yumurtalık kanseri hücrelerinde AZD-1390 ile ATM inhibisyonunun antikanser etkisini test ettik. Sonuçlarımız, AZD-1390'ın yumurtalık kanseri hücrelerinde doz ve zamana bağlı bir şekilde hücre canlılığını azaltarak antiproliferatif bir etki gösterdiğini gösterdi. Daha ileri analizler, AZD-1390'ın göç potansiyelini önemli ölçüde inhibe ettiğini ve ROS aktivitesini ve hücre ölümünü artırdığını ortaya koydu. Bulgularımız birlikte, AZD-1390 ile ATM inhibisyonunun yumurtalık kanseri hücrelerini tedavi etmede etkili olduğunu ve daha ileri araştırmaların bu çalışmaya katkıda bulunacağını göstermektedir.

Keywords

• ATM
• AZD-1390
• Yumurtalık Kanseri
• Hücre Proliferasyonu

AZD-1390 Impairs Cell Mobility and Induces ROS-triggered Apoptotic Cell Death in Ovarian Cancer Cell Lines

Abstract

The Ataxia Telangiectasia mutation (ATM) codes for a protein for serine/threonine kinase. Phosphorylation of ATM prevents tumor formation by preserving genomic integrity. Somatic mutations in the ATM gene have been identified in some types of ovarian cancer. Therefore, in this study, we tested the anticancer effects of ATM inhibition with AZD-1390 in ovarian cancer cells to eliminate these mutations. Our results showed that AZD-1390 exhibited an antiproliferative effect by decreasing cell viability in ovarian cancer cells in a dose- and time-dependent manner. Further analysis revealed that AZD-1390 significantly inhibited the migration potential and increased ROS activity and apoptotic cell death. Our findings together suggest that ATM inhibition with AZD-1390 is effective in treating ovarian cancer cells and further investigation will contribute to this study.

Keywords

• ATM
• AZD-1390
• Ovarian Cancer
• Cell Proliferation.

References

1. Beretta GL, Costantino M, Mirra L, Pettinari P, Perego P. Deubiquitinases in ovarian cancer: role in drug resistance and tumor aggressiveness. International Journal of Biological Sciences. 2024;20(13):5208–5222.
2. Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian cancer immunotherapy and personalized medicine. International Journal of Molecular Sciences. 2021;22(12):1–19.
3. Stewart C, Ralyea C, Lockwood, S. Ovarian cancer: an integrated review. Seminars in Oncology Nursing. 2019;35(2):151–156.
4. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Practice and Research: Clinical Obstetrics and Gynaecology. 2017;41: 3–14.
5. Perlman S, Becker-Catania S, Gatti RA. Ataxia-telangiectasia: diagnosis and treatment. Seminars in Pediatric Neurology. 2003;10(3):173–182.
6. Harris BRE, Zhang Y, Tao J, Shen R, Zhao X, Cleary MP, Wang T, Yang DQ. ATM inhibitor KU-55933 induces apoptosis and inhibits motility by blocking GLUT1-mediated glucose uptake in aggressive cancer cells with sustained activation of Akt. FASEB Journal. 2021;35(4):1–23.
7. Renault AL, Mebirouk N, Cavaciuti E, Le Gal D, Lecarpentier J, Dubois d’Enghien C, Laugé A, Dondon MG, Labbé M, Lesca G, Leroux D, Gladieff L, Adenis C, Faivre L, Gilbert-Dussardier B, Lortholary A, Fricker JP, Dahan K, Bay JO, Tinat J. Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia families. Carcinogenesis. 2017; 38(10): 994–1003.
8. Tseng CC, Ku MH, Wu YC, Huang WL, Wu WM, Pai CH, Chen CW. Therapeutic options targeting the Ataxia-Telangiectasia Mutated (ATM)-mediated DNA damage response, macropinocytosis, and adaptive immunity in ovarian cancer. Anticancer Research. 2024;44(4):1353–1364.

9. Kim HS, Choi SI, Min HL, Kim MA, Kim WH. Mutation at intronic repeats of the ataxia-telangiectasia mutated (ATM) gene and ATM protein loss in primary gastric cancer with microsatellite instability. PLoS ONE. 2013;8(12):1–10.
10. Graffeo R, Rana HQ, Conforti F, Bonanni B, Cardoso MJ, Paluch-Shimon S, Pagani O, Goldhirsch A, Partridge AH, Lambertini M, Garber JE. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. Breast. 2022;65(June):32–40.
11. Zhang A, Zhang L, Xie X, Liu D. Inhibition of ATM with KU-55933 sensitizes endometrial cancer cell lines to olaparib. OncoTargets and Therapy. 2023;16(December):1061–1071.
12. Cai H, Dai X, Guo X, Zhang L, Cao K, Yan F, Ji B, Liu Y. Ataxia telangiectasia mutated inhibitor-loaded copper sulfide nanoparticles for low-temperature photothermal therapy of hepatocellular carcinoma. Acta Biomaterialia. 2021;127:276–286.
13. Luo S, Lyu Z, Ge L, Li Y, Liu Y, Yuan Y, Zhao R, Huang L, Zhao J, Huang H, Luo Y. Ataxia telangiectasia mutated protects against lipopolysaccaride-induced blood-brain barrier disruption by regulating atk/drp1-medıated mitochondrial homeostasis. Shock. 2023;60(1):100–109.
14. Tseng CC, Ku MH, Wu YC, Huang WL, Wu WM, Pai CH, Chen CW. Therapeutic options targeting the ataxia-telangiectasia mutated (ATM)-mediated DNA damage response, macropinocytosis, and adaptive immunity in ovarian cancer. Anticancer Research. 2024;44(4):1353–1364.
15. Yang S, Song D, Wang Z, Su Y, Chen J, Xian Y, Huang J, Li J, Xu J, Zhao J, Liu Q. AKT/GSK3β/NFATc1 and ROS signal axes are involved in AZD1390-mediated inhibitory effects on osteoclast and OVX-induced osteoporosis. International Immunopharmacology. 2022;113(PA):109370.
16. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NMB, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GCM. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Research. 2004;64(24):9152–9159.
17. Xu Xue, Li Mengzhi, Hu Jun, Chen Zheng, Yu Jinyu, Dong Yan, Sun Chengtao, Han J. Somatic mitochondrial DNA D - loop mutations in meningioma discovered : A preliminary data A comprehensive overview of mitochondrial DNA 4977-bp. Journal of Cancer Research and Therapeutics. 2018;14(7):1525–1534.
18. Jucaite A, Stenkrona P, Cselényi Z, De Vita S, Buil-Bruna N, Varnäs K, Savage A, Varrone A, Johnström P, Schou M, Davison C, Sykes A, Pilla Reddy V, Hoch M, Vazquez-Romero A, Moein MM, Halldin C, Merchant MS, Pass M, Farde L. Brain exposure of the ATM inhibitor AZD1390 in humans - A positron emission tomography study. Neuro-Oncology. 2021;23(4):687–696.
19. Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, Yang Z, Riches L, Trinidad AG, Fok JHL, Hunt T, Pike KG, Wilson J, Smith A, Colclough N, Reddy VP, Sykes A, Janefeldt A, Johnström P, Pass M. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Science Advances. 2018;4(6).
20. Shen M, Xu Z, Xu W, Jiang K, Zhang F, Ding Q, Xu Z, Chen Y. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. Journal of Experimental and Clinical Cancer Research. 2019;38(1):1–14.
21. Dou X, Wang Z, Lu W, Miao L, Zhao Y. METTL3 promotes non-small cell lung cancer (NSCLC) cell proliferation and colony formation in a m6A-YTHDF1 dependent way. BMC Pulmonary Medicine. 2022;22(1):1–15.
22. Tang Q, Chen J, Di Z, Yuan W, Zhou Z, Liu Z, Han S, Liu Y, Ying G, Shu X, Di M. TM4SF1 promotes EMT and cancer stemness via the Wnt/β-catenin/SOX2 pathway in colorectal cancer. Journal of Experimental and Clinical Cancer Research. 2020;39(1):1–17.
23. Chen B, Song Y, Zhan Y, Zhou S, Ke J, Ao W, Zhang Y, Liang Q, He M, Li S, Xie F, Huang H, Chan WN, Cheung AHK, Ma BBY, Kang W, To KF, Xiao J. Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway. Cancer Letters. 2022;543(May):215783.
24. Xie C, Zhou X, Liang C, Li X, Ge M, Chen Y, Yin J, Zhu J, Zhong C. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer. Journal of Experimental and Clinical Cancer Research. 2021;40(1):1–18.
25. Huang Y, Yang L, Wang J, Yang F, Xiao Y, Xia R, Yuan X, Yan M. Twelve novel Atm mutations identified in chinese ataxia telangiectasia patients. NeuroMolecular Medicine. 2013;15(3):536–540.
26. Lavin MF, Scott S, Gueven N, Kozlov S, Peng C, Chen P. Functional consequences of sequence alterations in the ATM gene. DNA Repair. 2004;3(8–9):1197–1205.
27. Ahmed M, Li L, Pinnix C, Dabaja B, Nomie K, Lam L, Wang M. ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma. Critical Reviews in Oncology/Hematology. 2016;107:14–19.
28. Daniel JA, Pellegrini M, Lee BS, Guo Z, Filsuf D, Belkina NV, You Z, Paull TT, Sleckman BP, Feigenbaum L, Nussenzweig A. Loss of ATM kinase activity leads to embryonic lethality in mice. Journal of Cell Biology. 2012;198(3):295–304.
29. Abe K, Kitago M, Kitagawa Y, Hirasawa A. Hereditary pancreatic cancer. International Journal of Clinical Oncology. 2021;26(10):1784–1792.
30. Samuel D, Diaz-Barbe A, Pinto A, Schlumbrecht M, George S. Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2. Cells. 2022;11(3):1–16.
31. Zheng A, Wei Y, Zhao Y, Zhang T, Ma X. The role of cancer-associated mesothelial cells in the progression and therapy of ovarian cancer. Frontiers in Immunology. 2022;13(October):1–12.
32. Tang Q, Wang X, Wang H, Zhong L, Zou D. Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer. Cancer Biology and Medicine. 2023;20(12):915–921.
33. Özdemir D, Ağca CA. AZD1390, an Ataxia telangiectasia mutated inhibitor, enhances cisplatin mediated apoptosis in breast cancer cells. Experimental Cell Research. 2025;444(2):114382.
34. Chen J, Laverty DJ, Talele S, Bale A, Carlson BL, Porath KA, Bakken KK, Burgenske DM, Decker PA, Vaubel RA, Eckel-Passow JE, Bhargava R, Lou Z, Hamerlik P, Harley B, Elmquist WF, Nagel ZD, Gupta SK, Sarkaria JN. Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization. Science Translational Medicine. 2024;16(734).
35. Bailey J, Oliveri A, Levin E. 基因的改变NIH Public Access. Bone. 2013;23(1):1–7.
36. Wang N, Yu M, Fu Y, Ma Z. Blocking ATM attenuates SKOV3 cell proliferation and migration by disturbing OGT/OGA expression via hsa-miR-542-5p. Frontiers in Oncology. 2022;12(June):1–10.
37. Kim YH, Jo DS, Park NY, Bae J, Kim JB, Lee HJ, Kim SH, Kim SH, Lee S, Son M, Park K, Jeong K, Yeom E, Cho D. and ATM Activation. 2022.
38. Li C, Deng C, Wang S, Dong X, Dai B, Guo W, Guo Q, Feng Y, Xu H, Song X, Cao L. A novel role for the ROS-ATM-Chk2 axis mediated metabolic and cell cycle reprogramming in the M1 macrophage polarization. Redox Biology. 2024;70(February):103059.
39. Bester D, Blignaut M, Huisamen B. ATM facilitates autophagy and protects against oxidative stress and apoptosis in response to ER stress in vitro. Biochemical and Biophysical Research Communications. 2024;732(May).